Nektar Therapeutics (NKTR) Q3 Net Loss Widens to $55.7M as R&D Spending Rises

Nektar reported Q3 2026 revenue of $9.4M versus $11.8M a year earlier and a net loss of $55.7M versus $35.5M. Cash and marketable securities were $952.9M at September 30, 2026, versus $245.8M at December 31, 2025.Material DetailsContext by AI AnalystThis is a quarterly financial update during an ea…